Johnson & Johnson’s Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals for an exclusive, worldwide license to develop and commercialize a therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
A new frontier in the field of medicine, the gene-silencing class of drugs employs a principle known as RNA interference to block activity of a rogue gene.
Under the deal, Janssen will obtain a worldwide license for California-based Arrowhead’s ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology.
Read the press release